N-methylnicotinamide excretion and affective disorders

Area of Science:

• Biochemistry
• Psychiatry
• Genetics

Background:

• Primary affective disorders (PAD) have a complex etiology.
• Biomarkers for assessing PAD risk are crucial for early intervention.
• N-Methylnicotinamide (N1-MN) is a metabolite of niacin with potential biological significance.

Purpose of the Study:

• To investigate N-Methylnicotinamide (N1-MN) urinary output in patients with primary affective disorders (PAD), secondary affective disorders (SAD), and healthy controls.
• To determine if N1-MN levels correlate with genetic predisposition to PAD.

Main Methods:

• Urine samples were collected from 38 healthy volunteers, 52 SAD patients, 55 PAD patients, and 46 healthy first-degree relatives of PAD patients.
• Urinary N-Methylnicotinamide (N1-MN) output was quantified.
• Statistical analyses were performed to compare N1-MN levels across groups.

Main Results:

• A significantly higher frequency of low N1-MN excretion was observed in PAD patients and their first-degree relatives compared to healthy controls and SAD patients (P < 0.001).
• PAD patients exhibited consistently low N1-MN output, irrespective of clinical disease phase.
• Low N1-MN levels were identified as a potential biological marker associated with PAD.

Conclusions:

• Low N-Methylnicotinamide (N1-MN) urinary output may serve as a biological index for primary affective disorders (PAD).
• This biomarker could be linked to an increased risk of developing PAD.
• Further research is warranted to explore the theoretical implications and clinical utility of N1-MN levels in affective disorder assessment.